Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases - affecting the central nervous system and systemic indications - with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company's novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
03/14/23	$52,000,000	Series A	BOLD Capital Partners Digitalis Ventures Eli Lilly and Company Insight Partners Ono Venture Investment UCB Ventures Upfront Ventures	undisclosed